UCB (OTCMKTS:UCBJF) Shares Gap Up – What’s Next?

UCB SA (OTCMKTS:UCBJF) shares gapped up before the market opened on Wednesday. The stock had previously closed at $237.84, but opened at $250.34. UCB shares last traded at $250.34, with a volume of 52 shares traded.

Analyst Ratings Changes

Several research analysts have recently commented on the stock. Jefferies Financial Group raised shares of UCB to a “hold” rating in a research note on Monday, August 3rd. Piper Sandler reaffirmed a “neutral” rating on shares of UCB in a research note on Wednesday, July 22nd. Finally, Stephens reiterated an “overweight” rating on shares of UCB in a report on Wednesday. Five equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy”.

UCB Price Performance

The firm has a 50 day moving average price of $247.69 and a 200-day moving average price of $275.86. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78.

UCB Company Profile

UCB is a Belgium-based biopharmaceutical company focused on discovering, developing and commercializing medicines for people living with severe diseases. Its primary therapeutic areas are neurology and immunology, with research activities spanning conditions such as epilepsy, myasthenia gravis, Parkinson’s disease, psoriasis, psoriatic arthritis, axial spondyloarthritis and other immune-mediated disorders.

The company’s medicines include Bimzelx (bimekizumab), an immunology treatment; Cimzia (certolizumab pegol), used for several inflammatory conditions; and a portfolio of neurological therapies that includes Briviact (brivaracetam), Keppra (levetiracetam), Fintepla (fenfluramine) and Nayzilam (midazolam).